Upland, CA (PRWEB) October 09, 2014
Claremont BioSolutions, LLC, pioneer of rapid sample preparation technologies, today announced an agreement with SeraCare Life Sciences to supply synthetic stool matrix for use in its quality control products. ClaremontBio has developed products for sample preparation of difficult-to-handle samples such as sputum and stool and has particular expertise in developing biologically relevant reagent formulations that mimic these sample types.
SeraCare recently released its new ACCURUN® 501 C. difficile Control – the company’s first molecular control product targeting hospital acquired infections. C. difficile testing is performed by detecting bacterial DNA isolated from stool samples, an area that ClaremontBio has been pursuing in research supported by the National Institutes of Health over the past four years.
Under the agreement, Claremont BioSolutions will supply its proprietary synthetic stool formulations to SeraCare for use in its products and for the development of future products.
About Claremont BioSolutions, LLC.
Claremont BioSolutions (http://www.ClaremontBio.com) is a privately held, emerging growth technology company specializing in miniaturized, disposable devices that provide solutions to what is recognized as the “bottleneck” of DNA diagnostics – sample preparation. The company has developed proprietary disposable devices which employ micro-motors to perform very efficient mechanical tissue homogenization, cell lysis, and nucleic acid purification. Their efforts toward solving sample prep challenges with hard to handle sample matrices and pathogens have led the company to its development of unique reagents and buffers that are of broad interest in the diagnostics industry.
Gary Blackburn, Ph.D.
Chief Executive Officer
Claremont BioSolutions, LLC
Phone: (626) 825‐6962
Fax: (909) 946‐1132
Address: 1182 Monte Vista Ave., Suite 11
Upland, CA. 91786